SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As ‘Game Changer’ Ahead Of Final Trial Trigger
An AstraZeneca sales executive called the Phase 3 Regal trial a “game changer” for AML patients in their…
SLS, IBRX Catch The Eye Of A Major US Pension Fund — And Big Clinical Catalysts Are On The Horizon
Virginia Retirement System disclosed SLS and IBRX stakes worth nearly $909,000 combined. The $124 billion fund ranks as…